Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124959 | 0.92 | — | — | |
| SCHEMBL5582375 | 0.84 | — | — | |
| SCHEMBL1461682 | 0.83 | — | — | |
| SCHEMBL1461683 | 0.83 | — | — | |
| SCHEMBL21261840 | 0.83 | — | — | |
| SCHEMBL19018827 | 0.83 | — | — | |
| SCHEMBL3336999 | 0.83 | — | — | |
| SCHEMBL3337002 | 0.83 | — | — | |
| SCHEMBL20408899 | 0.83 | — | — | |
| SCHEMBL23961874 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778578-A1 | IMMUNOPROTEASOME INHIBITOR ANALOGS FOR TREATING INFLAMMATORY DISEASES | The Regents of the University of California (US) | 2021-02-17 | — | — | EP | claimed |
| US-10584105-B2 | Immunoproteasome inhibitor analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-10 | — | — | US | claimed |
| US-20190047969-A1 | IMMUNOPROTEASOME INHIBITOR ANALOGS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2019-02-14 | — | — | US | claimed |
| EP-3426641-A1 | IMMUNOPROTEASOME INHIBITOR ANALOGS | The Regents of the University of California (US) | 2019-01-16 | — | — | EP | claimed |
| WO-2017156471-A1 | IMMUNOPROTEASOME INHIBITOR ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-14 | — | — | WO | claimed |
| EP-2358726-B1 | POROUS REACTIVE FRAMEWORKS | UNIV CALIFORNIA (US) | 2017-08-02 | — | — | EP | claimed |
| US-9512145-B2 | Porous reactive framework | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-06 | — | — | US | claimed |
| US-20110319630-A1 | POROUS REACTIVE FRAMEWORK | BASF SE (DE) | 2011-12-29 | — | — | US | claimed |
| EP-2358726-A2 | POROUS REACTIVE FRAMEWORKS | The Regents of the University of California (US) | 2011-08-24 | — | — | EP | claimed |
| WO-2010080618-A2 | POROUS REACTIVE FRAMEWORKS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-15 | — | — | WO | claimed |
| US-20240216406-A1 | METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL | INTRINSIC MEDICINE INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240180939-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE ENHANCEMENT OF ANTI-TUMOR EFFICACY OF IMMUNO-ONCOLOGY AGENTS | TARGET CAPITAL 4 LLC | 2024-06-06 | — | — | US | disclosed |
| US-20240165137-A1 | METHODS FOR IMPROVING MUSCLE STRENGTH AND MOBILITY | TARGET CAPITAL 4 LLC | 2024-05-23 | — | — | US | disclosed |
| US-20240148040-A1 | METHODS OF REDUCING EXERCISE-INDUCED INJURY OR ENHANCING MUSCLE RECOVERY AFTER EXERCISE | TARGET CAPITAL 4 LLC | 2024-05-09 | — | — | US | disclosed |
| US-20240059646-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | ORGANIX INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055012-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180939-A1 | IMMUNOMODULATORY OLIGOSACCHARIDES FOR THE ENHANCEMENT OF ANTI-TUMOR EFFICACY OF IMMUNO-ONCOLOGY AGENTS | LGALS8, FUT6, LGALS4 | CXCR4 1529/4885SMN1; SMN2 634/4885ALDH1A1 4196/4885 |
| US-10584105-B2 | Immunoproteasome inhibitor analogs | PSMD8, PSMC5, PSMG3 | CXCR4 4802/4885SMN1; SMN2 384/4885ALDH1A1 4095/4885 |
| US-20240165137-A1 | METHODS FOR IMPROVING MUSCLE STRENGTH AND MOBILITY | MYOF, FUCA1, GYS1 | CXCR4 1580/4885SMN1; SMN2 191/4885ALDH1A1 2741/4885 |
| US-20190047969-A1 | IMMUNOPROTEASOME INHIBITOR ANALOGS | PSMD8, PSMC5, PSMG3 | CXCR4 4802/4885SMN1; SMN2 384/4885ALDH1A1 4095/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | CXCR4 2124/4885SMN1; SMN2 599/4885ALDH1A1 399/4885 |
| US-20240059646-A1 | RESORCINOL-BASED COMPOUNDS AND USES THEREOF | VHL, NQO1, HRAS | CXCR4 1685/4885SMN1; SMN2 2226/4885ALDH1A1 649/4885 |
| US-20240216406-A1 | METHODS AND COMPOSITIONS FOR SUPPORTING HUMAN HEALTH DURING SPACE TRAVEL | FUT6, FUT5, FUCA2 | CXCR4 76/4885SMN1; SMN2 130/4885ALDH1A1 4647/4885 |
| US-20110319630-A1 | POROUS REACTIVE FRAMEWORK | OGFR, EPCAM, PTGFR | CXCR4 405/4885SMN1; SMN2 4259/4885ALDH1A1 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.